The Future of Somatostatin Receptor Ligands in Acromegaly
Open Access
- 7 October 2021
- journal article
- review article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (2) , 297-308
Abstract
Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. Pasireotide, a second-generation SRL, shows higher efficacy with respect to both biochemical control and tumor shrinkage but has a worse safety profile. In this review, we discuss the future perspectives of currently available SRLs, focusing on the use of biomarkers of response and precision medicine, new formulations of these SRLs and new drugs, which are under development. Precision medicine, which is based on biomarkers of response to treatment, will help guide the decision-making process by allowing physicians to choose the appropriate drug for each patient and improving response rates. New formulations of available SRLs, such as oral, subcutaneous depot, and nasal octreotide, may improve patients’ adherence to treatment and quality of life since there will be more options available that better suit each patient. Finally, new drugs, such as paltusotine, somatropin, ONO-5788, and ONO-ST-468, may improve treatment adherence and present higher efficacy than currently available drugs.Keywords
This publication has 95 references indexed in Scilit:
- Meta-Analysis on the Effects of Octreotide on Tumor Mass in AcromegalyPLOS ONE, 2012
- Sporadic and genetic forms of paediatric somatotropinoma: a retrospective analysis of seven cases and a review of the literatureOrphanet Journal of Rare Diseases, 2011
- Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open‐label, multicentre studyClinical Endocrinology, 2009
- Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAREuropean Journal of Endocrinology, 2008
- The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenomaClinical Endocrinology, 2007
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Rationale for the use of somatostatin analogs as antitumor agentsAnnals of Oncology, 2006
- The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegalyEuropean Journal of Endocrinology, 2006
- Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 1999
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982